Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry

[1]  J. Witztum,et al.  Statin therapy increases lipoprotein(a) levels. , 2020, European heart journal.

[2]  E. Liberopoulos.  Lipoprotein(a) reduction with proprotein convertase subtilisin/kexin type 9 inhibitors: An unsolved mystery. , 2020, European journal of preventive cardiology.

[3]  Deepak L. Bhatt,et al.  Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. , 2020, Journal of the American College of Cardiology.

[4]  M. Mazidi,et al.  Low-carbohydrate diet: forget restriction, replace with balance! , 2019, European Heart Journal.

[5]  F. Kronenberg,et al.  Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM , 2019, Clinical chemistry and laboratory medicine.

[6]  M. Banach,et al.  Statins and Lp(a): do not make perfect the enemy of excellent. , 2019, European heart journal.

[7]  A. Sahebkar,et al.  Pulse wave velocity as a measure of arterial stiffness in patients with familial hypercholesterolemia: a systematic review and meta-analysis , 2019, Archives of medical science : AMS.

[8]  P. Toth,et al.  Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis , 2019, Lipids in Health and Disease.

[9]  C. Cannon,et al.  Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. , 2019, Atherosclerosis.

[10]  R. Santos,et al.  Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management. , 2019, Progress in cardiovascular diseases.

[11]  M. Sabatine,et al.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.

[12]  D. Panagiotakos,et al.  The role of lipoprotein (a) in primary and secondary cardiovascular disease prevention: a systematic review of epidemiological studies. , 2019, Current opinion in cardiology.

[13]  M. Banach,et al.  The prevalence and management of familial hypercholesterolemia in patients with acute coronary syndrome in the Polish tertiary centre: Results from the TERCET registry with 19,781 individuals. , 2019, Atherosclerosis.

[14]  P. Barter,et al.  Comparing a novel equation for calculating low-density lipoprotein cholesterol with the Friedewald equation: A VOYAGER analysis. , 2019, Clinical biochemistry.

[15]  F. Kronenberg,et al.  Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials , 2018, The Lancet.

[16]  G. Kolovou,et al.  Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). , 2018, Atherosclerosis.

[17]  F. Raal,et al.  Familial hypercholesterolemia treatments: Guidelines and new therapies. , 2018, Atherosclerosis.

[18]  A. Keech,et al.  Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial , 2019, Circulation.

[19]  A. Keech,et al.  Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial , 2018, JAMA cardiology.

[20]  J. Witztum,et al.  Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide. , 2018, Journal of clinical lipidology.

[21]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[22]  G. Chrousos,et al.  An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH) , 2017, Hormones.

[23]  J. Coresh,et al.  Accuracy of low-density lipoprotein cholesterol estimation at very low levels , 2017, BMC Medicine.

[24]  B. Nordestgaard,et al.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology , 2016, Journal of Lipid Research.

[25]  B. Nordestgaard,et al.  High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study. , 2016, The lancet. Diabetes & endocrinology.

[26]  J. Frohlich,et al.  Lipoprotein (a), an independent cardiovascular risk marker , 2016, Clinical Diabetes and Endocrinology.

[27]  G. Watts,et al.  Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia , 2015, Drugs.

[28]  U. Das,et al.  Potential role of dietary lipids in the prophylaxis of some clinical conditions , 2015, Archives of medical science : AMS.

[29]  J. Witztum,et al.  ‘LDL-C’ = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering , 2015, Current opinion in lipidology.

[30]  J. Borén,et al.  Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment , 2015, European heart journal.

[31]  J. Frohlich,et al.  Marked effects of extreme levels of lipoprotein(a) on estimation of low-density lipoprotein cholesterol. , 2014, Clinical biochemistry.

[32]  M. Elisaf,et al.  Reaching low density lipoprotein cholesterol targets , 2014, Current medical research and opinion.

[33]  M. Blaha,et al.  Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. , 2013, JAMA.

[34]  A. Cai,et al.  Lipoprotein(a): A Promising Marker for Residual Cardiovascular Risk Assessment , 2013, Disease markers.

[35]  Catherine Boileau,et al.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease , 2013, European heart journal.

[36]  M. Okubo,et al.  Lipoprotein(a)-cholesterol: a significant component of serum cholesterol. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[37]  Jennifer G. Robinson,et al.  Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. , 2011, Journal of clinical lipidology.

[38]  R. Krauss,et al.  Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet , 2010, Journal of Lipid Research.

[39]  J. Borén,et al.  Lipoprotein(a) as a cardiovascular risk factor: current status , 2010, European heart journal.

[40]  Emilio Ros,et al.  Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. , 2008, The American journal of cardiology.

[41]  U. Das,et al.  Lipids in Health and Disease BioMed Central Hypothesis , 2008 .

[42]  C. Cordova,et al.  Comparison of LDL-cholesterol direct measurement with the estimate using the Friedewald formula in a sample of 10,664 patients. , 2004, Arquivos brasileiros de cardiologia.

[43]  J. Kastelein,et al.  Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia , 2003, Heart.

[44]  N. Rifai,et al.  Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). , 2000, Clinical chemistry.

[45]  M. Elisaf,et al.  Lp(a) levels in Greek patients with heterozygous familial hypercholesterolemia. , 1996, International journal of cardiology.

[46]  D. Wilcken,et al.  Effect of serum lipoprotein(a) on estimation of low-density lipoprotein cholesterol by the Friedewald formula. , 1994, Clinical chemistry.

[47]  E. DeLong,et al.  A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol. The Lipid Research Clinics Prevalence Study. , 1986 .

[48]  A. Gotto,et al.  Human plasma lipoprotein [a]. Structural properties. , 1983, The Journal of biological chemistry.

[49]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[50]  M. Taskinen,et al.  [ESC/EAS Guidelines for the management of dyslipidaemias]. , 2011, Revista espanola de cardiologia.

[51]  P. Wilson,et al.  Calculated values for low-density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. , 1990, Clinical chemistry.